Board of directors
Redoxis board of directors consists of Rikard Holmdahl (chairman), Peter Olofsson (CEO) and Mona Wilcke.
 |
 |
 |
||
| Rikard Holmdahl – Chairman | Peter Olofsson, | Mona Wilcke, | ||
| Professor Rikard Holmdahl (PhD, MD) has been a professor of medical inflammation research since 1993 (Karolinska Institute, Stockholm since 2008 and Lund University from 1993 to 2007). He has been a professor at the Finnish Academy (Turku University) since 2006. Dr. Holmdahl is a member of scientific advisory boards of several companies including Resistentia AB, Oxypharma AB and Cartela AB and is currently a member of the board of Redoxis subsidiary ProNoxis AB. | Dr. Peter Olofsson has been the CEO of Redoxis AB since the company was founded in 2007. Dr. Olofsson holds a PhD from Lund University and an executive MBA from the Göteborg School of Economics and Law. Peter has held positions at companies such as Arexis AB and Biovitrum AB (publ). Peter is also a member of the board of Redoxis subsidiary ProNoxis AB. | Dr. Mona Wilcke holds a PhD in Biochemistry from Stockholm University. Dr Wilcke has gained broad experience with several companies in the life sciences industry, having served as a CEO, marketing director and director of investor relations. Dr. Wilcke is the owner of several patent applications and is a founder of Glucox Biotech AB where she is currently director of the board. |
